HB0025

DRUG3 trials

Sponsors

Huabo Biopharm Co., Ltd.

Conditions

Advanced Endometrial CancerAdvanced NSCLCRenal CancerTumor, Subjects

Phase 1

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Huabo Biopharm Co., Ltd.Tumor, Subjects

Start: 2021-03-10End: 2024-05-23Target: 154Updated: 2022-06-01

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

RecruitingNCT06758557

Huabo Biopharm Co., Ltd.Advanced Endometrial Cancer, Advanced NSCLC

Start: 2024-01-31End: 2026-02-28Target: 282Updated: 2025-01-23

Phase 2

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

RecruitingNCT06222125

Huabo Biopharm Co., Ltd.Renal Cancer

Start: 2023-01-30End: 2025-12-30Target: 100Updated: 2024-01-24

Related Papers

A phase II study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2026-05-28

A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer.

Journal of Clinical Oncology2025-05-283 citations

Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.

Journal of Clinical Oncology2024-06-011 citations

A phase 1/2 study to evaluate the efficacy and safety of HB0025 monotherapy for patients (pts) with advanced renal cell carcinoma (RCC).

Journal of Clinical Oncology2024-06-01

Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.

Journal of Clinical Oncology2023-06-014 citations